Is Rallybio Corp Stock a Good Investment?
Rallybio Corp Investment Advice | RLYB |
- Examine Rallybio Corp's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Rallybio Corp's leadership team and their track record. Good management can help Rallybio Corp navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Rallybio Corp's business and its evolving consumer preferences.
- Compare Rallybio Corp's performance and market position to its competitors. Analyze how Rallybio Corp is positioned in terms of product offerings, innovation, and market share.
- Check if Rallybio Corp pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Rallybio Corp's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Rallybio Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Rallybio Corp is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Rallybio Corp Stock
Researching Rallybio Corp's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 77.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rallybio Corp recorded a loss per share of 1.33. The entity had not issued any dividends in recent years.
To determine if Rallybio Corp is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rallybio Corp's research are outlined below:
| Rallybio Corp generated a negative expected return over the last 90 days | |
| Rallybio Corp has some characteristics of a very speculative penny stock | |
| Rallybio Corp has high historical volatility and very poor performance | |
| Rallybio Corp has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 636 K. Net Loss for the year was (57.77 M) with loss before overhead, payroll, taxes, and interest of (38.87 M). | |
| Rallybio Corp currently holds about 147.37 M in cash with (49.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Ryder Steven of 62000 shares of Rallybio Corp at 15.04 subject to Rule 16b-3 |
Rallybio Corp uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rallybio Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rallybio Corp's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Rallybio Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Rallybio Corp's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-13 | 2024-12-31 | -0.2967 | -0.25 | 0.0467 | 15 | ||
2024-03-12 | 2023-12-31 | -0.45 | -0.5 | -0.05 | 11 | ||
2023-11-09 | 2023-09-30 | -0.51 | -0.45 | 0.06 | 11 | ||
2023-05-09 | 2023-03-31 | -0.49 | -0.43 | 0.06 | 12 | ||
2022-11-07 | 2022-09-30 | -0.54 | -0.6 | -0.06 | 11 | ||
2024-11-07 | 2024-09-30 | -0.3381 | -0.26 | 0.0781 | 23 | ||
2023-03-06 | 2022-12-31 | -0.6 | -0.46 | 0.14 | 23 | ||
2021-11-10 | 2021-09-30 | -0.88 | -0.37 | 0.51 | 57 |
Know Rallybio Corp's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rallybio Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rallybio Corp backward and forwards among themselves. Rallybio Corp's institutional investor refers to the entity that pools money to purchase Rallybio Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Allostery Investments Lp | 2024-12-31 | 803.4 K | Laurion Capital Management Lp | 2024-12-31 | 735.5 K | Renaissance Technologies Corp | 2024-12-31 | 441.3 K | Mariner Wealth Advisors Llc | 2024-12-31 | 404.5 K | Millennium Management Llc | 2024-12-31 | 338.9 K | Geode Capital Management, Llc | 2024-12-31 | 247.8 K | Blackrock Inc | 2024-12-31 | 201.2 K | Northeast Financial Consultants, Inc | 2024-12-31 | 96.4 K | Bridgeway Capital Management, Llc | 2024-12-31 | 91.6 K | Viking Global Investors Lp | 2024-12-31 | 4.2 M | Johnson & Johnson | 2024-12-31 | 3.6 M |
Rallybio Corp's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.13 M.Market Cap |
|
Rallybio Corp's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | (0.94) | (0.89) |
Determining Rallybio Corp's profitability involves analyzing its financial statements and using various financial metrics to determine if Rallybio Corp is a good buy. For example, gross profit margin measures Rallybio Corp's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rallybio Corp's profitability and make more informed investment decisions.
Please note, the presentation of Rallybio Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rallybio Corp's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Rallybio Corp's management manipulating its earnings.
Evaluate Rallybio Corp's management efficiency
Rallybio Corp has return on total asset (ROA) of (0.3891) % which means that it has lost $0.3891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6885) %, meaning that it created substantial loss on money invested by shareholders. Rallybio Corp's management efficiency ratios could be used to measure how well Rallybio Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.89. In addition to that, Return On Capital Employed is expected to decline to -1.03. At present, Rallybio Corp's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 204.5 M, whereas Non Current Assets Total are forecasted to decline to about 253.7 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.42 | 1.70 | |
| Tangible Book Value Per Share | 1.42 | 1.70 | |
| Enterprise Value Over EBITDA | (0.46) | (0.49) | |
| Price Book Value Ratio | 0.68 | 0.71 | |
| Enterprise Value Multiple | (0.46) | (0.49) | |
| Price Fair Value | 0.68 | 0.71 | |
| Enterprise Value | 28.1 M | 26.7 M |
The strategic vision of Rallybio Corp management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta (1.45) |
Basic technical analysis of Rallybio Stock
As of the 21st of March, Rallybio Corp holds the Variance of 16.5, coefficient of variation of (645.39), and Risk Adjusted Performance of (0.13). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rallybio Corp, as well as the relationship between them.Rallybio Corp's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rallybio Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rallybio Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rallybio Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rallybio Corp's Outstanding Corporate Bonds
Rallybio Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rallybio Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rallybio bonds can be classified according to their maturity, which is the date when Rallybio Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US751277AS36 Corp BondUS751277AS36 | View | |
| RALPH LAUREN P Corp BondUS751212AC57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Rallybio Corp's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Rallybio Corp's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (1.61) | |||
| Mean Deviation | 3.12 | |||
| Coefficient Of Variation | (645.39) | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.5 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (1.62) | |||
| Maximum Drawdown | 17.68 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 6.32 | |||
| Skewness | 0.8422 | |||
| Kurtosis | 1.68 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (1.61) | |||
| Mean Deviation | 3.12 | |||
| Coefficient Of Variation | (645.39) | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.5 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (1.62) | |||
| Maximum Drawdown | 17.68 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 6.32 | |||
| Skewness | 0.8422 | |||
| Kurtosis | 1.68 |
Consider Rallybio Corp's intraday indicators
Rallybio Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rallybio Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Rallybio Corp time-series forecasting models is one of many Rallybio Corp's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rallybio Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Rallybio Stock media impact
Far too much social signal, news, headlines, and media speculation about Rallybio Corp that are available to investors today. That information is available publicly through Rallybio media outlets and privately through word of mouth or via Rallybio internal channels. However, regardless of the origin, that massive amount of Rallybio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Rallybio Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Rallybio Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Rallybio Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Rallybio Corp alpha.
Rallybio Corp Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Rallybio Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rallybio Corp Corporate Executives
Elected by the shareholders, the Rallybio Corp's board of directors comprises two types of representatives: Rallybio Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rallybio. The board's role is to monitor Rallybio Corp's management team and ensure that shareholders' interests are well served. Rallybio Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rallybio Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan MBA | CFO Treasurer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rallybio Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. If investors know Rallybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rallybio Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Rallybio Corp's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Rallybio Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rallybio Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.